In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ed Silverman

Set Alert for Articles By Ed Silverman

Latest From Ed Silverman

Proving The Value Of Value-Based Deals

As controversy continues over pharmaceutical pricing, more drugmakers are eyeing deals that peg health plan cost to outcomes to boost volume and win formulary placement. But these deals are challenging to construct and to date there is little evidence that they reduce costs for patients.

BioPharmaceutical Pricing Strategies

States Fight For Drug Price Transparency

California's Proposition 61 and a number of other state-led measures to control drug prices failed to gain traction in 2016. But states are likely to remain a battleground in the war against costs in a pharma-friendly Trump administration.

BioPharmaceutical Market Access

State Drug Cost/Price Transparency Legislation

A look at recent state legislation designed to require prescription drug cost and price transparency from prescription drug manufacturers. Data from the National Conference of State Legislatures.


Bio-Path Hopes To Blaze Profitable Path With Antisense Drugs

Bio-Path Holdings is trying to become the next company to make it big with antisense drugs. Recently, the Houston-based biotech released data showing its lead compound, which is known as BP-1001, may hold promise in treating advanced acute myeloid leukemia, or AML.

BioPharmaceutical Business Strategies

WaVe’s Well-Timed Series B

The RNA drugmaker raised its $66 million Series B just as the markets started to go south.


Axovant's IPO: Harbinger Of A Biotech Bubble?

In June, Axovant Sciences Ltd. launched an IPO in which its stock almost doubled on the first day of trading and its valuation approached a frothy $3 billion. And this startling performance was attributed to just one asset – an experimental compound for Alzheimer’s disease.

See All